Orexigen Therapeutics (OREX) 3.04 $OREX
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 30, 1:12PM CDT
What: Arena Pharmaceuticals was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year. So what: Sales of the duo's obesity drug, Belviq, were up 95% year over year for...
OREX: 3.04 (+0.05), ARNA: 1.89 (+0.07)
Betting Big on Beleaguered Biotechs
at The Street - Thu Oct 29, 3:00PM CDT
Investor's holdings have fallen along with the sector, but he's raising the stakes.
OREX: 3.04 (+0.05), BITI: 13.11 (-0.19), IBB: 325.46 (-3.09), ATRA: 25.77 (+0.14), KERX: 4.48 (-0.03)
Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2015 Financial Results on November 5, 2015
PR Newswire - Thu Oct 22, 3:15PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the third quarter 2015 on Thursday, November 5 after the market closes. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
OREX: 3.04 (+0.05)
3 Biotech Stocks We're Ready to Sell
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 9:38AM CDT
Image by PeteLinforth via Pixabay I (Brian Feroldi here!) always find it hard to hit the sell button on any stock, as it's nearly impossible to know if you are making the right decision at the time. It can be particularly difficult to part ways...
OREX: 3.04 (+0.05), BLCM: 12.51 (-0.50), SRPT: 24.06 (-0.57)
Why Zafgen Plummeted Today
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 16, 11:23AM CDT
What: It's been one hell of a week for Zafgen . Monday and Tuesday shares were down on worry that bad news was coming. On Wednesday, the biotech announced that there was a death in its trial testing beloranib in patients with a rare genetic...
OREX: 3.04 (+0.05), ZFGN: 9.63 (-0.33), ARNA: 1.89 (+0.07)
Here's Why Orexigen Therapeutics' Stock Tanked in September
George Budwell, The Motley Fool - Motley Fool - Sun Oct 11, 8:01AM CDT
OREX data by YCharts What : Shares of the anti-obesity drugmaker Orexigen Therapeutics lost nearly a quarter of their value in September based on data from S&P Capital IQ , easily outpacing the broader downturn among biopharma and...
OREX: 3.04 (+0.05)
Forget Big Pharma: These Little Stocks Offer Far Richer Investing Opportunities
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sat Oct 03, 8:03AM CDT
Photo by Bill Brooks via Flickr Creative Commons Large pharma stocks tend to be favorites in the investing community, as their huge size and diverse product portfolio offer investors safety when the market goes crazy. However, their huge size...
OREX: 3.04 (+0.05), DEPO: 17.50 (-0.74), IG: 7.68 (+1.41)
Orexigen sumbits Contrave's NDA to MFDS in South Korea for weight management in obese adults
M2 - Fri Oct 02, 6:34AM CDT
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) disclosed on Thursday the submission of a New Drug Application with the Ministry of Food and Drug Safety (MFDS) in South Korea for Contrave (naltrexone HCl and bupropion HCl) as a monotherapy for weight management in overweight or obese adult patients, a serious health problem in the country.
OREX: 3.04 (+0.05)
Orexigen Announces Submission of Contrave® New Drug Application in South Korea
PR Newswire - Thu Oct 01, 7:45AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Kwang Dong Pharmaceutical Company, Ltd., has filed a New Drug Application with the Ministry of Food and Drug Safety (MFDS) in South Korea for Contrave® (naltrexone HCl and bupropion HCl) as a monotherapy for weight management in overweight or obese adult patients. If approved, Kwang Dong will market and distribute Contrave as part of its distributorship agreement with Orexigen's wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd., executed in August 2015.
OREX: 3.04 (+0.05)
10 Worst NASDAQ Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:43PM CDT
The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.
VSTM: 1.84 (+0.01), OREX: 3.04 (+0.05), TTPH: 9.03 (+0.02), IMMU: 2.99 (+0.08), RPTP: 5.45 (-0.31), CLDX: 12.06 (-0.22), THRX: 8.78 (-0.03), ARNA: 1.89 (+0.07), KPTI: 13.35 (+0.11), XOMA: 1.22 (+0.04)
5 Sell-Ranked Biotechs That Fell More Than 5% Today
A Clark - Zacks Investment Research - Fri Sep 25, 4:53PM CDT
The biotech sector has been struggling as of late, and Friday was an especially tough day for many biotech stocks. Read on for 5 stocks that suffered losses of at least 5% on the day.
BLUE: 77.13 (-1.96), OREX: 3.04 (+0.05), ALDR: 31.98 (-0.08), ACAD: 34.82 (-1.15), ANIP: 41.84 (-1.30)
Orexigen Receives $22M Milestone Payment for Contrave
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 4:00PM CDT
Orexigen Therapeutics (OREX) received a total of $22 million in milestone payments for its obesity drug, Contrave, from its partners, Takeda and Kwang Dong.
OREX: 3.04 (+0.05), GILD: 108.13 (-1.08), REGN: 557.39 (-2.63)
Orexigen receives first USD15m anniversary milestone payment for Contrave
M2 - Thu Sep 24, 4:45AM CDT
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) disclosed on Wednesday that it has received the first USD15m anniversary milestone payments for Contrave (naltrexone HCl and bupropion HCl extended release).
OREX: 3.04 (+0.05)
Commit To Purchase Orexigen Therapeutics At $2.50, Earn 28.5% Annualized Using Options
StockOptionsChannel.com - Wed Sep 23, 11:01AM CDT
Investors considering a purchase of Orexigen Therapeutics, Inc. stock, but tentative about paying the going market price of $2.50/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OREX: 3.04 (+0.05)
Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners
PR Newswire - Wed Sep 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen's United States partner for Contrave® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are expected from Takeda in the fourth quarter of each of 2016 and 2017.
OREX: 3.04 (+0.05)
Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 18, 8:21PM CDT
Last December, Orexigen received a positive opinion from the Committee for Medicinal Products For Human Use, or CHMP, on the application to market its obesity drug Mysimba in the EU. That's essentially an approval in the EU, although it requires...
OREX: 3.04 (+0.05), VVUS: 1.26 (-0.08), ARNA: 1.89 (+0.07)
Orexigen announces USD60m from sale of common shares to Baupost
M2 - Fri Sep 11, 4:48AM CDT
Orexigen Therapeutics (NasdaqGS:OREX) stated on Thursday that it has raised USD60m from the sale of stock to funds managed by The Baupost Group in a private placement.
OREX: 3.04 (+0.05)
Here's Why Orexigen Therapeutics' Stock Briefly Spiked Today
George Budwell, The Motley Fool - Motley Fool - Thu Sep 10, 10:48AM CDT
What : Shares of Orexigen Therapeutics , a biotech company focusing on the development of anti-obesity medicines, saw its shares briefly rise by as much as 23% on exceptional volume today. This rocket-like rise was sparked by the announcement that...
OREX: 3.04 (+0.05)
Orexigen Therapeutics (OREX) Stock Climbs on $60 Million Investment
at The Street - Thu Sep 10, 10:30AM CDT
Orexigen Therapeutics (OREX) shares are rising after the company sold $60 million worth of common stock to Baupost Group.
OREX: 3.04 (+0.05)
Hot Stock: Orexigen Therapeutics, Shares Gain 7.3% (OREX)
Comtex SmarTrend(R) - Thu Sep 10, 10:17AM CDT
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 7.3% to $2.81 on 1.5x average daily volume. Orexigen Therapeutics has traded 3.9 million shares thus far today, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (7.3% to the Dow's 0.4%) and outperformed the S&P 500 (7.3% to the S&P's 0.4%) during today's trading.
OREX: 3.04 (+0.05)
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 30, 1:12PM CDT
What: Arena Pharmaceuticals was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year. So what: Sales of the duo's obesity drug, Belviq, were up 95% year over year for...
OREX: 3.04 (+0.05), ARNA: 1.89 (+0.07)
Betting Big on Beleaguered Biotechs
at The Street - Thu Oct 29, 3:00PM CDT
Investor's holdings have fallen along with the sector, but he's raising the stakes.
OREX: 3.04 (+0.05), BITI: 13.11 (-0.19), IBB: 325.46 (-3.09), ATRA: 25.77 (+0.14), KERX: 4.48 (-0.03)
Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2015 Financial Results on November 5, 2015
PR Newswire - Thu Oct 22, 3:15PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the third quarter 2015 on Thursday, November 5 after the market closes. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
OREX: 3.04 (+0.05)
3 Biotech Stocks We're Ready to Sell
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Oct 18, 9:38AM CDT
Image by PeteLinforth via Pixabay I (Brian Feroldi here!) always find it hard to hit the sell button on any stock, as it's nearly impossible to know if you are making the right decision at the time. It can be particularly difficult to part ways...
OREX: 3.04 (+0.05), BLCM: 12.51 (-0.50), SRPT: 24.06 (-0.57)
Why Zafgen Plummeted Today
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 16, 11:23AM CDT
What: It's been one hell of a week for Zafgen . Monday and Tuesday shares were down on worry that bad news was coming. On Wednesday, the biotech announced that there was a death in its trial testing beloranib in patients with a rare genetic...
OREX: 3.04 (+0.05), ZFGN: 9.63 (-0.33), ARNA: 1.89 (+0.07)
Here's Why Orexigen Therapeutics' Stock Tanked in September
George Budwell, The Motley Fool - Motley Fool - Sun Oct 11, 8:01AM CDT
OREX data by YCharts What : Shares of the anti-obesity drugmaker Orexigen Therapeutics lost nearly a quarter of their value in September based on data from S&P Capital IQ , easily outpacing the broader downturn among biopharma and...
OREX: 3.04 (+0.05)
Forget Big Pharma: These Little Stocks Offer Far Richer Investing Opportunities
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sat Oct 03, 8:03AM CDT
Photo by Bill Brooks via Flickr Creative Commons Large pharma stocks tend to be favorites in the investing community, as their huge size and diverse product portfolio offer investors safety when the market goes crazy. However, their huge size...
OREX: 3.04 (+0.05), DEPO: 17.50 (-0.74), IG: 7.68 (+1.41)
Orexigen sumbits Contrave's NDA to MFDS in South Korea for weight management in obese adults
M2 - Fri Oct 02, 6:34AM CDT
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) disclosed on Thursday the submission of a New Drug Application with the Ministry of Food and Drug Safety (MFDS) in South Korea for Contrave (naltrexone HCl and bupropion HCl) as a monotherapy for weight management in overweight or obese adult patients, a serious health problem in the country.
OREX: 3.04 (+0.05)
Orexigen Announces Submission of Contrave® New Drug Application in South Korea
PR Newswire - Thu Oct 01, 7:45AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Kwang Dong Pharmaceutical Company, Ltd., has filed a New Drug Application with the Ministry of Food and Drug Safety (MFDS) in South Korea for Contrave® (naltrexone HCl and bupropion HCl) as a monotherapy for weight management in overweight or obese adult patients. If approved, Kwang Dong will market and distribute Contrave as part of its distributorship agreement with Orexigen's wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd., executed in August 2015.
OREX: 3.04 (+0.05)
10 Worst NASDAQ Biotech Stocks in the Third Quarter
at The Street - Wed Sep 30, 3:43PM CDT
The third quarter was brutal for biotech stocks. Here are the companies that fared the worst.
VSTM: 1.84 (+0.01), OREX: 3.04 (+0.05), TTPH: 9.03 (+0.02), IMMU: 2.99 (+0.08), RPTP: 5.45 (-0.31), CLDX: 12.06 (-0.22), THRX: 8.78 (-0.03), ARNA: 1.89 (+0.07), KPTI: 13.35 (+0.11), XOMA: 1.22 (+0.04)
5 Sell-Ranked Biotechs That Fell More Than 5% Today
A Clark - Zacks Investment Research - Fri Sep 25, 4:53PM CDT
The biotech sector has been struggling as of late, and Friday was an especially tough day for many biotech stocks. Read on for 5 stocks that suffered losses of at least 5% on the day.
BLUE: 77.13 (-1.96), OREX: 3.04 (+0.05), ALDR: 31.98 (-0.08), ACAD: 34.82 (-1.15), ANIP: 41.84 (-1.30)
Orexigen Receives $22M Milestone Payment for Contrave
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 4:00PM CDT
Orexigen Therapeutics (OREX) received a total of $22 million in milestone payments for its obesity drug, Contrave, from its partners, Takeda and Kwang Dong.
OREX: 3.04 (+0.05), GILD: 108.13 (-1.08), REGN: 557.39 (-2.63)
Orexigen receives first USD15m anniversary milestone payment for Contrave
M2 - Thu Sep 24, 4:45AM CDT
Biopharmaceutical company Orexigen Therapeutics (NasdaqGS:OREX) disclosed on Wednesday that it has received the first USD15m anniversary milestone payments for Contrave (naltrexone HCl and bupropion HCl extended release).
OREX: 3.04 (+0.05)
Commit To Purchase Orexigen Therapeutics At $2.50, Earn 28.5% Annualized Using Options
StockOptionsChannel.com - Wed Sep 23, 11:01AM CDT
Investors considering a purchase of Orexigen Therapeutics, Inc. stock, but tentative about paying the going market price of $2.50/share, might benefit from considering selling puts among the alternative strategies at their disposal.
OREX: 3.04 (+0.05)
Orexigen Receives Payments Totaling $22 Million from U.S. and Korean Partners
PR Newswire - Wed Sep 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals, Orexigen's United States partner for Contrave® (naltrexone HCl and bupropion HCl extended release). Two additional potential $15 million anniversary milestone payments are expected from Takeda in the fourth quarter of each of 2016 and 2017.
OREX: 3.04 (+0.05)
Why Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 18, 8:21PM CDT
Last December, Orexigen received a positive opinion from the Committee for Medicinal Products For Human Use, or CHMP, on the application to market its obesity drug Mysimba in the EU. That's essentially an approval in the EU, although it requires...
OREX: 3.04 (+0.05), VVUS: 1.26 (-0.08), ARNA: 1.89 (+0.07)
Orexigen announces USD60m from sale of common shares to Baupost
M2 - Fri Sep 11, 4:48AM CDT
Orexigen Therapeutics (NasdaqGS:OREX) stated on Thursday that it has raised USD60m from the sale of stock to funds managed by The Baupost Group in a private placement.
OREX: 3.04 (+0.05)
Here's Why Orexigen Therapeutics' Stock Briefly Spiked Today
George Budwell, The Motley Fool - Motley Fool - Thu Sep 10, 10:48AM CDT
What : Shares of Orexigen Therapeutics , a biotech company focusing on the development of anti-obesity medicines, saw its shares briefly rise by as much as 23% on exceptional volume today. This rocket-like rise was sparked by the announcement that...
OREX: 3.04 (+0.05)
Orexigen Therapeutics (OREX) Stock Climbs on $60 Million Investment
at The Street - Thu Sep 10, 10:30AM CDT
Orexigen Therapeutics (OREX) shares are rising after the company sold $60 million worth of common stock to Baupost Group.
OREX: 3.04 (+0.05)
Hot Stock: Orexigen Therapeutics, Shares Gain 7.3% (OREX)
Comtex SmarTrend(R) - Thu Sep 10, 10:17AM CDT
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 7.3% to $2.81 on 1.5x average daily volume. Orexigen Therapeutics has traded 3.9 million shares thus far today, vs. average volume of 2.6 million shares per day. The stock has outperformed the Dow (7.3% to the Dow's 0.4%) and outperformed the S&P 500 (7.3% to the S&P's 0.4%) during today's trading.
OREX: 3.04 (+0.05)
